[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amyloid-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amyloid-cardiomyopathy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,52,81,106,134,160,189,214,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100559420","phase-3-acoramidis-transthyretin-amyloidosis-prevention-trial-in-the-young-act-early-study-in-asymptomatic-carriers-of-a-pathogenic-ttr-variant-100559420",false,"NCT06563895","Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","Key Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 75 years of age inclusive.\n* Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M\u002Fp.V50M, V122I\u002Fp.V142I, T60A\u002Fp.T80A, or all other pathogenic TTR variants).\n* Participant's age is within 10 years younger than or older than PADO.\n\nKey Exclusion Criteria:\n\n* Evidence of ATTR-CM or ATTR-PN.\n* Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.\n* Contraindication to or inability to undergo cardiac magnetic resonance testing.\n* Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy\n* Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.\n* Major surgery within the past 3 months or planned during the next 12 months.\n* Known hypersensitivity to acoramidis.","ALL","18 Years","75 Years",{"count":20,"type":21},587,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.\n\nAmyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.\n\nAcoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.\n\nThis study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.",[27,28,29,30,31,32],"Amyloidosis","Amyloid Cardiomyopathy","Transthyretin Amyloidosis","Cardiomyopathies","Heart Diseases","Polyneuropathies",[27,34,35,36,37,38],"ATTR-CM","ATTR-PN","Transthyretin","Amyloid","TTR","RECRUITING","2026-06-25",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":43},"2025-05-12",{"date":47,"type":21},"2032-12",{"name":49,"class":50},"Eidos Therapeutics, a BridgeBio company","INDUSTRY",103,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100611458","phase-4-enavogliflozin-for-the-management-of-patients-with-amyloid-cardiomyopathy-100611458","NCT07240844","Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy","Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy - A Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter Trial","EMPACT","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Diagnosed with amyloid cardiomyopathy confirmed by cardiac biopsy or non-invasive imaging\n3. Presence of heart failure symptoms corresponding to NYHA functional class II-III\n4. Patients on stable oral diuretic use, without dose changes exceeding 50% of the previous dose, for at least 2 weeks prior to study enrollment\n5. Ambulatory (able to walk)\n6. Able to provide written informed consent for study participation\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women\n2. Active infection\n3. Major cardiovascular events (e.g., myocardial infarction, stroke) within the past 6 months\n4. Scheduled for coronary revascularization, CRT-D implantation, atrial flutter\u002Ffibrillation ablation, or valve surgery\n5. History of heart transplantation\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² (calculated by CKD-EPI formula)\n7. No history of cancer within the past 5 years at screening (except borderline cancers without recurrence for 2-3 years; multiple myeloma with cardiac involvement is classified as cardiac amyloidosis and is exempt)\n8. Heart failure primarily caused by severe left sided valvular disease or ischemic heart disease (except if valvular disease is corrected)\n9. Type 1 diabetes mellitus or insulin-dependent diabetes\n10. History of ketoacidosis, complicated urinary or genital infections, or kidney stones\n11. Systolic blood pressure \\\u003C 80 mmHg or symptomatic hypotension\n12. Major surgery within 90 days prior to enrollment\n13. Known hypersensitivity or allergic reaction to the study drug or its components\n14. Moderate to severe liver impairment\n15. Chronic alcohol or substance abuse\n16. Residing in long-term care facilities (e.g., nursing homes)\n17. Unable to understand or comply with study drug, procedures, or follow-up, or who are deemed by the investigator to be unlikely to complete the study","19 Years",{"count":62,"type":21},68,[64],"PHASE4","This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.",[28],[28,68,69],"Enavogliflozin","Sodium-Glucose Cotransporter 2 Inhibitor","2026-06-16",{"date":72,"type":43},"2026-06-18",{"date":74,"type":43},"2026-01-06",{"date":76,"type":21},"2027-05-31",{"name":78,"class":79},"Seoul St. Mary's Hospital","OTHER",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100622323","myocardial-perfusion-cmr-for-differentiating-and-characterizing-hypertrophic-cardiomyopathy-phenotypes-100622323","NCT07382128","Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes","MyoPerf-HCM","Inclusion Criteria:\n\n* A confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype, according to current ESC guidelines; or a first-degree relative of a patient with a confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype; or a carrier of a genetic mutation for hypertrophic cardiomyopathy (carriers).\n* Patient with an indication to undergo cardiac magnetic resonance imaging (CMR) according to current ESC guidelines.\n* Age ≥ 18 years\n* Written informed consent obtained\n\nExclusion Criteria:\n\n\\- History of previous myocardial infarction or myocardial revascularization (coronary artery bypass grafting or percutaneous coronary angioplasty) and\u002For evidence of coronary stenosis ≥ 50% on coronary CT scan or invasive coronary angiography.",{"count":89,"type":21},250,"OBSERVATIONAL","This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease (AFD), and cardiac amyloidosis. The study will also include first-degree relatives of affected patients and genetic mutation carriers. By comparing myocardial blood flow and perfusion patterns across these different conditions, the study seeks to identify distinctive perfusion signatures that may improve diagnostic differentiation, support risk stratification, and provide insights into the role of ischemia in fibrosis progression, arrhythmias, and long-term outcomes.",[93,94,95,28],"HCM - Hypertrophic Cardiomyopathy","Anderson Fabry Disease","Cardiac Magnetic Resonance Imaging","2026-01-26",{"date":98,"type":43},"2026-02-02",{"date":100,"type":43},"2025-06-01",{"date":102,"type":21},"2027-06-01",{"name":104,"class":79},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":123,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100601897","phase-3-to-evaluate-the-long-term-safety-and-tolerability-of-acoramidis-in-participants-with-newly-diagnosed-attr-cm-act-early-ole-100601897","NCT07116473","To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)","A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)","Key Inclusion Criteria:\n\nParticipants must have completed the AG10-501 study (ACT-EARLY study) within the past 60 calendar days with a diagnosis of ATTR-CM (based on the AG10-501 protocol definition of ATTR-CM).\n\nKey Exclusion Criteria:\n\n1. Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only, or who permanently discontinued study drug prior to diagnosis of ATTR-CM in AG10-501.\n2. History of AL or another non-TTR amyloid subtype (eg, ApoA-1, gelsolin).\n3. History of a monoclonal paraprotein or abnormal light chains in serum or urine (i.e., MGUS) in which AL has not been ruled out.\n4. Stage IV or V chronic kidney disease (corresponding to an eGFR ≤ 29 mL\u002Fmin\u002F1.73 m2), or undergoing renal dialysis, or recipient of a kidney transplant.\n5. Active malignancy, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix that has been successfully treated. In the event a participant developed a low-grade and treatable malignancy in the AG10-501 study (eg, low-grade, localized prostate cancer) and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10-504 after documentation with the Medical Monitor.\n6. History of any organ transplant (with the exception of corneal transplant).\n7. Known hypersensitivity to acoramidis or any of the excipients within the study drug.\n8. Treatment for ATTR-CM with any ATTR-oriented on- or off-label or OTC product.",{"count":89,"type":21},[24],"The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).",[117,118,28,119,120,121,30,122,32,27],"Amyloidosis in Transthyretin (TTR)","Amyloidosis, Familial","Amyloid Cardiomyopathy, Transthyretin-Related","Amyloidogenic Transthyretin (ATTR) Amyloidosis","Heart Disease","Amyloidosis, Hereditary, Transthyretin-Related",[34,35,27,36,37,38,124],"Hereditary","NOT_YET_RECRUITING","2025-08-07",{"date":128,"type":43},"2025-08-11",{"date":130,"type":21},"2025-11",{"date":132,"type":21},"2037-12",{"name":49,"class":50},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":105},"100564817","phase-1-genistein-in-transthyretin-receptor-amyloid-cardiomyopathy-100564817","NCT06634108","Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy","Cardiovascular Genistein Therapy for Heart Failure Inflammation","GASPAR","Inclusion Criteria:\n\n* Age: 40-80 years\n* Heart failure with Reduced Ejection Fraction\n\n  * ischemic or nonischemic etiology\n  * LVEF \\\u003C40% by echocardiography, MUGA, or MRI\n* ATTR cardiomyopathy\n\n  * any LVEF by echocardiography, MUGA, or MRI\n* Stable optimally tolerated dosages of HF therapies for 3 months with no change in medical management regimen for at least 1 month\n* NT-proBNP\n\n  * for participants \\\u003C 75 years old with NT-proBNP \\> 125 pg\u002FmL\n  * for participants \\> 75 years old with NT-proBNP \\> 450 pg\u002FmL\n\nExclusion Criteria:\n\n* Coronary intervention in the past 3 months\n* Pregnancy\n* Endometriosis\n* Uterine fibroids\n* Cancer:\n\n  * including breast cancer\n  * predisposition to cancer such as abnormal mammogram\n  * family history\n  * BRCA1 or BRCA2 positive\n  * Patients on a vegan diet\n* Patients taking supplements such as isoflavonoid, genistein, or resveratrol\n* Ethanol abuse\n* Men: \\>4 drinks on any day or more than 14 drinks per week\n* Women: \\>3 drinks on any day or more than 7 drinks per week\n* Liver dysfunction:\n\n  * aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3X ULN\n  * total bilirubin greater than 1.5 times ULN\n* hormone replacement therapy (HRT)\n* thyroid supplement\n* Renal dysfunction (eGFR less than 25 mL\u002Fmin\u002F1.73 m2)\n* Uncontrolled diabetes (HgbA1c \\>10%)\n* Coagulopathies\n* Cytopenia:\n\n  * leukocytopenia\n  * hemoglobin \\\u003C 9 mg\u002Fdl\n  * platelets \\\u003C100x103\u002Fmm3\n* Any patients who had been hospitalized in the past 3 months for reasons other than heart failure\n* NYHA Functional Class I or Functional Class IV symptoms.\n* Acute bacterial or viral infectious disease, or acute exacerbation of a chronic infectious disease\n* allergy to genistein or inulin\n* allergy to perflutren dye used in contrast echocardiography","40 Years","80 Years",{"count":145,"type":21},20,[147,148],"PHASE1","PHASE2","This Phase 1b\u002F2a study aims to investigate the safety and efficacy of genistein in patients with Transthyretin (TTR) Amyloidosis. The focus is on its impact on inflammatory and cardiometabolic biomarkers, along with the effects on cardiac function and exercise capacity.\n\nBlood samples will be collected at baseline, following each dose of genistein, and after a six-week placebo washout period. These samples will undergo extensive analyses, including profiling for inflammatory cytokines and novel molecular markers, and routine tests like CBC, Chem 7, LFT, HbA1c, NT-proBNP, CRP, troponin T, and serum TTR. RNA-seq analyses on peripheral blood mononuclear cells (PBMCs) and isolation of plasma exosomes for inflammatory biomarkers are also part of the protocol.\n\nFollowing ESC\u002FAHA guidelines, echocardiography will assess cardiac structure and function, focusing on the left and right ventricles and valvular function. Additionally, exercise capacity will be evaluated through a standardized 6-minute walk test, and NT-proBNP levels will be measured as a cardiac stress biomarker.\n\nThe trial will include an 18-week follow-up period post-enrolment, with the primary endpoint being the change in inflammatory markers from baseline to three months. Secondary endpoints are cardiac function and exercise capacity changes over the same timeframe. This study aims to provide significant insights into genistein's therapeutic potential for TTR Amyloidosis and its broader implications in managing heart failure.\n\nFollowing ethical committee approval and written informed consent, the Investigators aim is to enroll 40 participants. This is an open-label study. Each patient will receive genistein by mouth: 250 mg twice a day for 4 weeks (500 mg total\u002Fday), 500 mg twice a day for 4 weeks (1000 mg total\u002Fday), and 750 mg twice a day (1500 mg total\u002Fday) for an additional 4 weeks. This will be followed by a 6-week washout period to conclude the study. An 18-month study is anticipated based on the average enrollment rates. Results from this study are expected to offer critical insights for future larger studies.",[28],"2025-06-12",{"date":153,"type":43},"2025-06-15",{"date":155,"type":43},"2024-09-27",{"date":157,"type":21},"2025-12-01",{"name":159,"class":79},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":169,"studyType":90,"phases":4,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100422130","swiss-cardiac-amyloidosis-registry-swiss-care-100422130","NCT04776824","Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)","B-CARE","Inclusion Criteria:\n\n* Confirmed diagnosis of amyloidosis w\u002Fwo cardiac involvement\n* General Consent\n\nExclusion Criteria:\n\n* Inability to give consent or existence of a written or documented oral refusal of the data subject.\\\u003C18 years of age",{"count":168,"type":21},300,"10 Years","Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and systolic dysfunction to the development of terminal heart failure. Recently, treatment options for TTR amyloidosis have become available. However costs for therapy are enormous and previous trials were not able to differentiate between patients that might benefit from treatment and those without a need for treatment.\n\nthe investigators study aims to determine markers, as assessed by cardiac magnet resonance imaging (CMR) feature tracking (FT) and T1- and T2- mapping, that might reliably indicate disease severity and could help to identify patients that might benefit from (ongoing) TTR stabilization treatment.",[28],[173,174,175,176,177,178],"Cardiac Amyloidosis","Tafamidis","CMR feature tracking","Strain","T1 and T2 Mapping","Outcomes","2025-05-01",{"date":181,"type":43},"2025-05-06",{"date":183,"type":43},"2001-02-22",{"date":185,"type":21},"2031-05-01",{"name":187,"class":79},"Insel Gruppe AG, University Hospital Bern",7,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":105},"100500561","exercise-training-in-transthyretin-cardiac-amyloidosis-100500561","NCT05797857","Exercise Training in Transthyretin Cardiac Amyloidosis","Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac Amyloidosis","Inclusion Criteria:\n\n* Diagnosis and typing of ATTR-CM by endomyocardial biopsy or by Grade 2 or Grade 3 pyrophosphate (PYP) positivity (exception: nonamyloid control arm in aim 1).\n\n  * Diagnosis of heart failure, with prior or current need of diuretics and increased N-terminal prohormone B-natureitic peptide (BNP) (≥450 pg\u002Fml).\n  * Peak VO2 \\\u003C80% predicted, indicating impaired aerobic capacity (for aim 2 only).\n  * Taking tafamidis (for aim 2 only)\n  * Able to walk 4 meters (with or without the use of an assistive device) and independent with basic activities of daily living at the time of enrolment.\n  * Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention.\n  * Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.\n\nExclusion Criteria:\n\n* Acute myocardial infarction (Note: given that cardiac biomarkers such as troponin are frequently elevated in ATTR-CM patients, the diagnosis of acute myocardial infarction should be based on clinical diagnosis, not biomarkers alone)\n\n  * \\>70% obstructive coronary artery disease\n  * Severe aortic valve stenosis\n  * Already actively participating in formal, facility-based cardiac exercise\n  * Already engaging in regular moderate to vigorous exercise conditioning defined as \\> 30 minutes per day, ≥ twice per week consistently during the previous 6 weeks\n  * Ventricular assist device\n  * Light chain amyloidosis or other form of non-ATTR amyloidosis\n  * Advanced chronic kidney disease defined as estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73m2\n  * Any organ transplantation\n  * Terminal illness other than HF with life expectancy \\\u003C 1 year\n  * Pacemaker or implantable cardioverter-defibrillato (ICD) with heart rate limits \\\u003C expected heart rates for exercise and unable to be reprogrammed\n  * Neuropathy due to transthyretin (TTR) mutation\n  * Impairment from stroke, injury or other medical disorder that precludes participation in the intervention\n  * Abnormal cardiopulmonary exercise testing (CPET) finding that requires further investigation and management\n  * Dementia that precludes ability to participate in exercise and follow study protocols\n  * High risk for non-adherence as determined by screening evaluation\n  * Inability or unwillingness to comply with the study requirements","60 Years","90 Years",{"count":199,"type":21},40,[201],"NA","Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patients on optimal treatment for transthyretin cardiac amyloidosis. This is a vital next step to improve functional capacity and quality of life of people suffering from transthyretin cardiac amyloidosis.",[28,204],"Transthyretin Cardiac Amyloidosis","2025-03-14",{"date":207,"type":43},"2025-03-18",{"date":209,"type":43},"2024-07-10",{"date":211,"type":21},"2030-06-30",{"name":213,"class":79},"Brigham and Women's Hospital",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":222,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":225,"conditions":226,"keywords":234,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100573590","ai-enabled-screening-and-diagnosis-of-cardiomyopathies-using-coronary-cta-100573590","NCT06748261","AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA","Artificial Intelligence-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary Computer Tomography Angiography","Atlantis","Cardiomyopathy cohort:\n\n* Inclusion Criteria:\n\n  1. A clinical diagnosis of cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, cardiac amyloidosis, myocarditis, arrhythmogenic right ventricular cardiomyopathy, and coronary artery disease\u002Fischemic heart disease.\n  2. At least one CCTA before surgery or implantable device treatment.\n* Exclusion Criteria:\n\n  1. No recorded diagnosis of cardiomyopathy or undetermined type of cardiomyopathy.\n  2. A clinical diagnosis of secondary cardiac abnormalities due to other organic or systemic diseases.\n  3. Surgery or implantable device treatment before CCTA examination.\n\nControl cohort:\n\n* Inclusion Criteria: participants with at least one CCTA examination.\n* Exclusion Criteria: clinical diagnosis of cardiovascular diseases (including cardiomyopathy, history of myocardial infarction, history of cardiac surgery, stent implantation, ICD implantation and so on) or secondary cardiac abnormalities due to systemic diseases.",true,{"count":224,"type":21},5000,"The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in patients with suspected coronary artery diseases. This study aims to develop a computerized CCTA interpretation using artificial intelligence for multi-label classification task to assist cardiomyopathy diagnosis in the clinical workflow.",[227,228,229,230,28,231,232,233,30],"Cardiovascular Diseases","Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Restrictive Cardiomyopathy","Ischemic Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy","Myocarditis",[235,30,236,237],"Cardiac computer tomography angiography","Artificial intelligence","Diagnosis","2024-12-23",{"date":240,"type":43},"2024-12-27",{"date":242,"type":21},"2024-12-30",{"date":244,"type":21},"2025-12-30",{"name":246,"class":79},"Shanghai Zhongshan Hospital",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":263,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100554436","eoss-attr-study-ehealth-based-operative-support-system-in-attr-cm-100554436","NCT06499064","EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","Information and Communications Technology (ICT)-based Modeling of Transthyretin-associated Amyloidosis Cardiomyopathies (ATTR-CM) Care: EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","eOSS-ATTR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* HF diagnosis according to European Society of Cardiology (ESC)\n* Patients with a HF decompensation in the last 12 months\n* Confirmed diagnosis of ATTR-CM (ATTRv or ATTRwt)\n* Written informed consent\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Participation in another clinical trial\n* Moderate or severe cognitive impairment without a competent caregiver\n* Lack of social support\n* Institutionalized patients\n* Life expectancy less than 1 year (excluding HF)\n* Institutional-based or end-of-life care\n* Serious psychiatric illness\n* Planned cardiac surgery\n* Planned heart transplantation or left ventricular assist device (LVAD) implant\n* Patients in haemodialysis program\n* The patient is unable or unwilling to give the informed consent to participate\n* The patient is considered an unsuitable candidate for this study according to the decision of the local investigator\n* Unstable patients with signs of fluid overload or low cardiac output",{"count":256,"type":21},50,[201],"Unicenter, proof-of-concept, prospective, randomised, controlled, open-label and blinded end-point adjudication trial to assess the effect on patient-reported outcomes measures (PROMs), patient-reported experience measures (PREMs) and clinical events of a mHealth-based comprehensive management program for patients with chronic heart failure (HF) due to transthyretin-associated amyloidosis (ATTR)-cardiomyopathy (CM) by means of remote daily telemonitoring of signs and symptoms and remote structured follow-up using videoconference.",[260,28,261,262],"Heart Failure","ATTR Amyloidosis Wild Type","ATTR Gene Mutation",[264],"eHealth; mHealth; telemonitoring; ATTR, heart failure","2024-10-21",{"date":267,"type":43},"2024-10-23",{"date":269,"type":21},"2024-12-01",{"date":271,"type":21},"2026-03-15",{"name":273,"class":79},"Hospital Universitari de Bellvitge"]